 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from scanned originals with text recognition applied 
(searchable text may contain so me errors and/or omissions) 
 
 
,,,'~~ .· '~ ~i ,-,,~ 
-k·~~ ( ,.-;;1/ 
2 Date: ~It 8h er MAJORITY 
3 JUDICIARY L.D. 793 
(Filing No. S-3]b) 
4 Reproduced and distributed under the direction of the Secretary of the Senate. 
5 STATE OF MAINE 
6 SENATE 
7 129TH LEGISLATURE 
8 FIRST REGULAR SESSION 
9 COMMITTEE AMENDMENT "f1 " to S.P. 237, L.D. 793, Bill, "An Act To 
10 Improve Accountability of Opioid Manufacturers" 
11 Amend the bill by striking out everything after the enacting clause and inserting the 
12 following: 
13 'Sec. 1. 5 MRSA §20010 is enacted to read: 
14 §20010. Opioid Use Disorder Prevention and Treatment Fund 
15 1. Fund established. The Opioid Use Disorder Prevention and Treatment Fund, 
16 referred to in this section as "the fund," is established for the purpose of supporting opioid 
17 use disorder analysis. prevention and treatment and is administered by the department. 
18 The fund consists of: 
19 A. Money received from proceeds from the registration fee under Title 32. section 
20 13800-C; 
21 B. Money received from proceeds from the fee under Title 32, section 13724, less 
22 $325, which may be retained by the Department of Professional and Financial 
23 Regulation; and 
24 C. Appropriations. allocations and contributions from private and public sources. 
25 The fund must be held separate and apart from all other money. funds and accounts. 
26 Eligible investment earnings credited to the assets of the fund become part of the assets of 
27 the fund. Any unexpended balances remaining in the fund at the end of any fiscal year do 
28 not lapse and must be carried forward to the next fiscal year. 
29 2. Uses of fund proceeds. The proceeds of the fund must be used for the following 
30 purposes: 
31 A. Opioid use disorder prevention services; 
32 B. Opioid use disorder treatment services. including: 
Page 1 -129LR1130(02)-1 
COMMITTEE AMENDMENT 
COMMITTEE AMENDMENT" A "to S.P. 237, L.D. 793 l 5 -5 80) 
(1) Inpatient and outpatient treatment programs and facilities, including short-
2 term and long-term residential treatment programs and sober living facilities; 
3 (2) Treating substance use disorder for the underinsured and uninsured; and 
4 (3) Research regarding opioid use disorder prevention and treatment; 
5 C. The department's reasonable expenses in administering the fund; and 
6 D. The Maine Board of Pharmacy's reasonable expenses in administering Title 32, 
7 section 13800-C and in providing the report required under Title 32, section 13800-C. 
8 The department shall award grants and contracts from proceeds of the fund to persons and 
9 organizations to carry out the purposes of the fund. 
10 Sec. 2. 22 MRSA §7249-B is enacted to read: 
11 §7249-B. Opioid medication distribution monitoring information 
12 A manufacturer of an opioid medication that is available in this State and a 
13 wholesaler that sells or distributes an opioid medication in this State shall submit to the 
14 department, by electronic means or other format specified in a waiver granted by the 
15 department, information for this State submitted to the United States Drug Enforcement 
16 Administration's Automation of Reports and Consolidated Orders System pursuant to 21 
17 United States Code, Subchapter I and 21 Code of Federal Regulations, Section 1304.33 at 
18 the time that information is submitted to the United States Drug Enforcement 
19 Administration. As used in this section, the terms "manufacturer" and "opioid 
20 medication" have the same meanings as in Title 32, section 13702-A. 
21 Sec. 3. 32 MRSA §13724, as amended by PL 2007, c. 402, Pt. DD, §11 and PL 
22 2011, c. 286, Pt. B, §5, is repealed and the following enacted in its place: 
23 §13724. Fees 
24 The Director of the Office of Professional and Occupational Regulation may establish 
25 by rule fees for purposes authorized under this chapter in amounts that are reasonable and 
26 necessary for their respective purposes in accordance with this section. Rules adopted 
27 pursuant to this section are routine technical rules as defined in Title 5, chapter 375, 
28 subchapter 2-A. 
29 1. General fees. Except as provided in subsection 2, the fee for any one purpose 
30 may not exceed $325. 
31 2. Manufacturer of an opioid medication fee. The fee for a manufacturer of an 
32 opioid medication is $55,000. 
33 Sec. 4. 32 MRSA §13800-C is enacted to read: 
34 §13800-C. Opioid medication product registration fee 
35 This section governs opioid medication product registration fees. As used in this 
36 section, "unit of an opioid medication" means the lowest identifiable quantity of the 
37 opioid medication that is dispensed. 
Page 2-129LR1130(02)-1 
COMMITTEE AMENDMENT 
COMMITTEEAMEND:MENT" f\ "to S.P. 237, L.D. 793 ( S-· 396) 
1 1. Registration fee. Except as provided in subsection 2, a manufacturer that sells, 
2 delivers or distributes an opioid medication in this State shall pay an annual registration 
3 fee of $250.000 to the board on December 31st of each year. 
4 2. Exception. A manufacturer that does not sell, deliver or distribute 2.000.000 or 
5 more units of an opioid medication within this State in the year in which a registration fee 
6 is due is not required to pay the registration fee. To qualify for the exception under this 
7 subsection. a manufacturer must demonstrate to the board. by January 31st of the year 
8 following the year in which the registration fee is due, in a manner determined by the 
9 board. that the manufacturer did not sell. deliver or distribute 2,000,000 or more units of 
10 an opioid medication within this State in the year in which the manufacturer seeks to 
11 claim the exception. The board may adopt rules to implement this section. Rules adopted 
12 pursuant to this subsection are routine technical rules as defined in Title 5, chapter 375, 
13 subchapter 2-A. 
14 3. Calculation of units of an opioid medication sold, delivered or distributed. 
15 When calculating the number of units of an opioid medication sold. delivered or 
16 distributed by a manufacturer under subsection 2, units of an opioid medication may be 
17 excluded when prescribed for the purpose of medication-assisted treatment of substance 
18 use disorder. The board periodically shall provide to the Department of Health and 
19 Human Services a list of medications exempted under this subsection. 
20 4. Registration fee review and report. By March 1st of each year following 
21 calendar years 2020. 2021 and 2022. the board shall evaluate and report whether the 
22 registration fee due under this section and the fee due under section 13 724 have affected 
23 the prescribing practices of opioid medications by reducing the number of opioid 
24 medication prescriptions issued during calendar years 2020. 2021 and 2022 or whether 
25 the fees have created any unintended consequences in the availability of opioid 
26 medications for the treatment of chronic or intractable pain, to the extent the board has 
27 the ability to identify a correlation. The board shall provide the report to the joint standing 
28 committee of the Legislature having jurisdiction over health and human services matters. 
29 which may report out legislation based upon the report. 
30 This subsection is repealed September 1, 2023. 
31 Sec. 5. Appropriations and allocations. The following appropriations and 
32 allocations are made. 
33 HEALTH AND HUMAN SERVICES, DEPARTMENT OF 
34 Opioid Use Disorder Prevention and Treatment Fund N307 
35 Initiative: Provides base allocation for the Opioid Use Disorder Prevention and Treatment 
36 Fund. 
37 
38 
39 
40 OTHER SPECIAL REVENUE FUNDS 
All Other 
OTHER SPECIAL REVENUE FUNDS TOTAL 
Page 3 -129LR1130(02)-1 2019-20 
$500 
$500 
COMMITTEE AMENDMENT 2020-21 
$500 
$500 
COMMITTEE AMENDMENT" 11" to S.P. 237, L.D. 793 (S-3d0 
HEALTH AND HUMAN SERVICES, 
DEPARTMENT OF 1 
2 
3 
4 
5 
6 
7 DEPARTMENT TOTALS 2019-20 
OTHER SPECIAL REVENUE FUNDS $500 
DEPARTMENT TOTAL-ALL FUNDS $500 
8 PROFESSIONAL AND FINANCIAL REGULATION, DEPARTMENT OF 
9 Licensing and Enforcement 0352 2020-21 
$500 · 
$500 
10 Initiative: Allocates funds for the contracting and general operating costs associated with 
11 the development of the registration fee review report, determination and report of 
12 exempted medications, rulemaking and additional board meetings. 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 OTHER SPECIAL REVENUE FUNDS 
All Other 
OTHER SPECIAL REVENUE FUNDS TOTAL 
PROFESSIONAL AND FINANCIAL 
REGULATION, DEPARTMENT OF 
DEPARTMENT TOTALS 
OTHER SPECIAL REVENUE FUNDS 
DEPARTMENT TOTAL-ALL FUNDS 
SECTION TOTALS 
OTHER SPECIAL REVENUE FUNDS 
SECTION TOTAL -ALL FUNDS 
30 SUMMARY 
31 This amendment replaces the bill. 2019-20 
$53,000 
$53,000 
2019-20 
$53,000 
--$53,000 
2019-20 
$53,500 
$53,500 2020-21 
$53,000 
$53,000 
2020-21 
$53,000 
$53,000 
2020-21 
$53,500 
$53,500 
32 The amendment raises the annual fee for a manufacturer of opioid medication to 
33 $55,000. The amendment establishes a registration fee due from manufacturers of opioid 
34 medications of $250,000 if the manufacturer sells, delivers or distributes 2,000,000 or 
35 more units of an opioid medication within this State, not including units that are 
36 prescribed for the purpose of medication-assisted treatment of substance use disorder. 
37 The fees are deposited into the Opioid Use Disorder Prevention and Treatment Fund, 
Page 4 -129LR1130(02)-1 
COMMITTEE AMENDMENT 
COMMITTEE AMENDMENT"(-\ "to S.P. 237,L.D. 793 ( 6-39Cl 
1 which is established to provide opioid use disorder prevention and treatment services and 
2 administered by the Department of Health and Human Services. 
3 The amendment also requires manufacturers and wholesale distributors of opioid 
4 medications to provide to the State the same information as provided to the United States 
5 Drug Enforcement Administration under its Automation of Reports and Consolidated 
6 Orders System regarding controlled substances transactions in this State on the same 
7 schedule that information is provided to the Federal Government. 
8 The amendment requires the Maine Board of Pharmacy to evaluate and report 
9 whether the fees have affected the prescribing practices for opioid medications by 
10 reducing the number of opioid medication prescriptions issued during calendar years 
11 2020, 2021 and 2022 or whether the fees have created any unintended consequences in 
12 the availability of opioid medications for the treatment of chronic or intractable pain, to 
13 the extent the board has the ability to identify a correlation. The board shall provide the 
14 report to the joint standing committee of the Legislature having jurisdiction over health 
15 and human services matters, which may report out legislation based upon the report. The 
16 reports must be submitted annually by March 1st. 
17 FISCAL NOTE REQUIRED 
18 (See attached) 
Page 5 -129LR1130(02)-1 
COMMITTEE AMENDMENT 
Approved: 06/14/19 :tPae 
129th MAINE LEGISLATURE 
LD793 LR 1130(02) 
An Act To Improve Accountability of Opioid Manufacturers 
Fiscal Note for Bill as Amended by Committee Amendment "A" { S-GS)0,\ 
Committee: Judiciary .) ) 
Fiscal Note Required: Yes 
Fiscal Note 
Current biennium revenue increase -Other Special Revenue Funds 
FY2019-20 FY2020-21 Projections 
FY 2021-22 Projections 
FY2022-23 
Appropriations/ Allocations 
Other Special Revenue Funds $53,500 $53,500 $53,500 $3,50( 
Fiscal Detail and Notes 
This bill includes Other Special Revenue Funds allocations of $53,000 in fiscal year 2019-20 and $53,000 in fiscal 
year 2020-21 to the Licensing and Enforcement program within the Depaiiment of Professional and Financial 
Regulation for the contracting and general operating costs associated with the development of the registration fee 
review report, determination and report of exempted medications, rulemaking and additional board meetings. 
This bill raises the annual license fee for a manufacturer of opiod medication to $55,000 and establishes an annual 
registration fee of $250,000 for a manufacturer of an opioid product that sells, delivers or distributes an opioid 
medication in the State and requires that the revenue from these fees, excluding $325 per license that may be retained 
by the Department of Professional and Financial Regulation, be credited to the Opiod Use Disorder Prevention and 
Treatment Fund. The estimated revenue to be received from the license and registration fees can not be estimated at 
this time. 
The bill also includes Other Special Revenue Funds allocations to the Department of Health and Human Services of 
$500 beginning in fiscal year 2019-20 for the base allocation for the Opioid Use Disorder Prevention and Treatment 
Fund. 
LRl 130(02) -Fiscal Note -Page 1 of 1 
